The 3rd China International Pharma, Biotech & Chemical Intellectual Property Forum Attracts Worldwide Attention to China Medical City, Taizhou
The Tri-State Chinese-American Chemical Society (CACS), together with the American Chemical Society (ACS) and the China Intellectual Property Society (CIPS), the Committee of Pharmaceutical Intellectual Property Rights Research of Chinese Pharmaceutical Association, and the Intellectual Property Office of Jiangsu Province, successfully held the 3rd International Pharma, Biotech & Chemical Intellectual Property Forum in China Medical City, Taizhou on May 24-27, 2012. The 3rd China IP Forum attracted an international audience of over 300. The organizing committee of the 3rd China IP Forum was co-chaired by Marinda Li Wu, President-Elect of American Chemical Society, and John D. Conway, Global Head of Innovative Healthcare Patent Support, Sanofi. The Forum received strong support from the local host, China Medical City and Taizhou Government, Jiangsu, China. The 3rd China IP Forum primarily focused on global IP protection, technology transfer and innovation commercialization. The Forum also featured a Patented Innovation Press Conference, which provided a unique platform for communication and exchange of intellectual property opportunities between Chinese and international pharmaceutical and chemical companies and institutions, as well as a day-long workshop co-organized by the 3rd China IP Forum and the Chinese Academy of Sciences.
SIPO Deputy Commissioner Mr. GAN Shaoning presided over the opening ceremony on the first day. Mr. ZHANG Lei, the General Secretary of CPC, Taizhou, Dr. Marinda Li Wu, President-Elect of the American Chemical Society, Mr. DENG Maicun, Secretary General of Chinese Academy of Sciences, and Mr. HE Quan, Deputy Governor of Jiangsu Province, gave opening remarks. Mr. TIAN Lipu, SIPO Commissioner, and Mr. David Kappos, Under Secretary of US Commerce and Director of USPTO, gave plenary keynote speeches at the opening session of the IP Forum. Mr. Tian presented an overview of the operations of China Patent System servicing innovation and promoting development within China. In his plenary keynote speech, Mr. Kappos focused on how the America Invents Act enhances global commerce. Following the opening plenary session, Judge Sharon Prost of the US Court of Appeals for the Federal Circuit presented a keynote on her view from the bench, talking about patent law taking center stage in the 21st century. Chief Justice KONG Xiangjun of the Intellectual Property Tribunal of the Supreme People’s Court of China spoke about “China IP Protection,” and Mr. Robert DeBerardine, the Vice President and Global Head of Patents of Sanofi, discussed “legal certainty and business investment” in his keynote speech. The morning sessions ended with the Press Conference on Patented Innovations where representatives from Sanofi, Cornell, Rutgers, and Stanford from the US, and Jiangsu Haohua Internet of Things Technology, Jiangsu Antae, and Jiangsu Mole Bioscience from China highlighted some of their patented technologies and sought opportunities for licensing and collaborations.
IP Executives from leading international pharmaceutical companies such as Sanofi, Amgen, and Bayer gave speeches at the IP Form. They emphasized the importance of IP protection in encouraging innovation and maintaining high rates of inventiveness in the pharmaceutical and biotech industry. They also elaborated on the effect of government policies, such as the Hatch-Waxman Act, on innovative vs. generic drug companies. Different from other industries, the pharmaceutical and biotech industry provides new innovative medicines to cure diseases and improve lives. To develop these new medications, the industry needs to invest precious resources in protracted, risky, and expensive pharmaceutical research and development processes. A strong IP system is necessary to ensure that these investments will make a profit. Without adequate IP protection, there won’t be sufficient incentives to develop new innovative medicines.
Speakers at the 3rd China IP Forum also included IP experts from well-known law firms, such as Finnegan Henderson, Birtch Stewart Kolasch Birth LLC (BSKB), Hoffmann Eitle, Kim & Chang, Simmons & Simmons, Buchanan Ingersoll & Rooney PC, Hogan Lovells, Ella Cheong Spruson & Ferguson, China Patent Agent (HK) Ltd., NTD Patent & Trademark Agency Ltd., Liu Shen & Associates, and CCPIT. They presented a variety of topics on patent prosecution and enforcement in several plenary sessions during the IP Forum. The first plenary session on “Inventions and Patent Strategies” included two sub-sessions: one focused on Comparisons in Patent Examination in Europe, US, Japan and China; and the second focused on Patent Prosecution and IP Protection in these countries and regions. Patent examination officials who spoke at the first session included Mr. ZHANG Qingkui, Director General of the Pharmaceutical and Biological Invention Examination Department of SIPO, Dr. George Elliott, Director for TC 1600 (Biotechnology and Organic Chemistry) of USPTO, Dr. Dieter Tzschoppe, Director of Pharmacy of the European Patent Office, and Mr. Satoshi Moriyasu, Deputy Director General of the 3rd Patent Examination Department of Japan Patent Office. They presented and discussed their respective country/region's standards for patentability, with a focus on an inventive step (non-obviousness) and enablement, including data disclosure in regards to the breadth of claims that may be granted. In the second session, senior patent attorneys from the US, Europe, Korea, and other Asian countries presented and discussed their patent application preparation and prosecution strategies to address the patentability standards of USPTO, EPO, KIPO, JPO, and SIPO, with an emphasis on addressing the patentability standards in their home country/region.
Day two of the IP Forum emphasized technology transfer and IP protection during externalization and outsourcing as well as patenting of biotech inventions. The plenary session on “Invention, Externalization and IP Transfer” included two sessions. One focused on Invention, IP Transfer and Commercialization by Universities and academic research. Topics in this session included how to turn innovative ideas from academic institutions into economic activities that create jobs and financial returns. Among the panel members who shared their valuable experiences were experts from some of the world's most prominent and successful organizations in technology transfer including Wisconsin Alumni Research Foundation (WARF) and Yeda Research and Development Co. of Israel. The second session featured panel members from pharmas and contract research organizations (CROs) on topics of IP protection during externalization & CRO outsourcing. In sessions under Biological Development & Invention Enforcement, speakers discussed the new challenges on obtaining and enforcing patents on biotech inventions and recent developments in patent litigation in Europe and US.
The third day of the IP Forum featured a session on China Pharmaceutical hot topics from drug pricing policies to practices, from pharmaceutical data protection to trademark issues and a roundtable discussion on patent procurement and enforcement in China. The panelists of the roundtable discussion included those from judicial branch, SIPO, multinational pharma, domestic pharma, and private practice. They had an interactive dialogue on hot issues in patent protection and enforcement in pharmaceutical and life science areas in China. The topics included how to protect innovations via strong patents, how to effectively enforce patents, and what should be taken into consideration when making deals.
The Tri-State CACS Secretary, Ms. Sunny Wang, was one of the main organizers of this 3rd China IP Forum and served as the international coordinator of the Organizing Committee. Chinese-American Chemical Society is a non-profit organization made up of volunteers. For over three decades, the CACS has been striving towards building bridges between the US and China in areas of interest to chemical professionals and chemical enterprises, towards building bridges to other communities and organizations so that our collective voices are heard and our mutual interests are advanced, and towards building bridges among Chinese, American, and Chinese-American chemical professionals to help their effort to excel in this wonderful world of chemical transformation. It is very much in keeping with our role of bridge-building that the CACS initiated and organized the 1st Beijing Pharmaceutical and Chemical IP Forum six years ago, the 2nd Beijing IP Forum three years ago and now the 3rd China IP Forum in China Medical City, Taizhou. As stated in the closing remarks by Dr. Fanwen Zeng, President of the Tri-State CACS, “we at CACS understood the importance of establishing strong IP systems in this age of global competition and rapid technological innovation.”
The workshop co-organized by the 3rd China IP Forum international Committee and Chinese Academy of Sciences on May 28th, 2012 focused on “Patent Information” and “IP Transfer”. It was well received by the audience, who were mainly from prestigious research institutes in China.
The 3rd China IP forum received strong sponsorship from many companies and law firms including Sanofi, Amgen, Finnegan Henderson, Scully Scott Murphy & Presser PC (SSMP), BSKB, Hoffmann Eitle, Kim & Chang, Simmons & Simmons, Buchanan Ingersoll & Rooney PC, Hogan Lovells,, Ella Cheong Spruson & Ferguson, China Patent Agent (HK) Ltd., NTD Patent & Trademark Agency Ltd., Liu Shen & Associates and CCPIT.
(Reported by Longqin Hu)
The 3rd China Pharma, Biotech & Chemical IP Forum & Innovation Press Conference